Estimating the cost effectiveness of alternative drug treatments for postmenopausal osteoporosis

Author: Ohsfeldt, Robert L

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 4, Number 6, December 2004 , pp. 637-644(8)

Publisher: Expert Reviews

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The burden of postmenopausal osteoporosis is substantial and is likely to grow as the baby-boom generation ages. A greater understanding of the costs and clinical benefits of alternative therapies for postmenopausal osteoporosis is needed to develop informed health policies to reduce the future burden of osteoporosis. However, much of the data needed to evaluate the cost effectiveness of alternative therapies for postmenopausal osteoporosis are not available from clinical trials. Thus, cost-effectiveness models must cope with a high degree of uncertainty. This article provides a brief summary of the methodologic issues in cost-effectiveness analyses of current osteoporosis therapies, a review of the findings in published cost-effectiveness studies, and a discussion of challenges likely to be encountered in future economic evaluations of emerging osteoporosis therapies.

Keywords: cost effectiveness; drug therapy; osteoporosis; postmenopausal

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737167.4.6.637

Publication date: 2004-12-01

More about this publication?

Expert Review of Pharmacoeconomics & Outcomes Research provides expert commentary on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites